Zura Bio Limited ZURA

No annual revenue total was found in Zura Bio Limited's SEC filings.

Zura Bio Limited (ZURA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$64.9 million.

Revenue
—
Net income (TTM)
$-93.53M
-43.7% vs year-ago TTM
Operating cash flow (TTM)
$-64.83M
-496.6% vs year-ago TTM
Free cash flow (TTM)
$-64.94M
-495.2% vs year-ago TTM
EPS (TTM)
$-1.06
-57.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
94.88M
+38.8% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ZURA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
La Jolla, CA
SEC filer status
, Emerging growth company
SEC CIK
1855644
Former names
JATT Acquisition Corp (until Mar 21, 2023)

Other Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating income
-$75.2M
-$55.2M
-$62.6M
-$27.2M
Net income
-$68.7M
-$52.4M
-$60.4M
-$25.7M
Diluted EPS
-$1.06
-$0.60
-$2.09
—
Operating cash flow
-$64.8M
-$28.1M
-$15.1M
-$1.2M
Free cash flow
-$64.9M
-$28.2M
—
—
Total assets
$113.9M
$179.5M
$100.8M
$5.3M
Total liabilities
$12.4M
$19.5M
$21.3M
$14.8M
Stockholders' equity
$101.5M
$146.8M
$59.3M
-$32.1M
Cash and investments
$109.4M
$176.5M
$99.8M
$13,785

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Results of operations, Regulation FD disclosure
Oct 27, 2026 Oct 27, 2026
10-Q Quarterly report Oct 27, 2026 Sep 30, 2026
8-K Current report
Regulation FD disclosure
Aug 17, 2026 Aug 17, 2026
8-K Current report
Results of operations, Regulation FD disclosure
Aug 11, 2026 Aug 11, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Regulation FD disclosure
Jul 1, 2026 Jul 1, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.